Yes, and the drop is bigger than you might expect. C-reactive protein, or CRP, is a protein your liver makes when your body is inflamed, and it's one of the easiest inflammation markers to pick up on an ordinary blood test. In the STEP 1 trial, CRP fell 44% more on semaglutide 2.4 mg than on placebo over 68 weeks.1 Tirzepatide did something similar in a SURMOUNT-1 analysis, with CRP down as much as 64.5% at 72 weeks.2 The more interesting question, and the one almost nobody answers honestly, is whether the drug is doing that directly, or whether it's just what happens when you lose a meaningful amount of weight.
The Quick Answer
Both semaglutide and tirzepatide lowered inflammation markers by a lot in their big phase 3 trials. Semaglutide 2.4 mg cut CRP versus placebo by 44% in STEP 1, 39% in STEP 2, and 48% in STEP 3 at week 68.1 Tirzepatide dropped CRP by 50.6% to 64.5%, and another inflammation marker called IL-6 by 25.4% to 30.2%, at 72 weeks in a SURMOUNT-1 analysis.2 But here's the honest part: no one has proven this is a drug effect separate from the weight loss. The semaglutide researchers said so themselves, writing that the question "remains to be determined."1
What "Inflammation" Actually Means Here
Inflammation is a word that gets stretched to cover almost anything, so it helps to narrow it down. The trials here measured specific proteins in the blood, mostly two of them.
C-reactive protein (CRP) is made by your liver whenever there's inflammation somewhere in the body. The sensitive version of the test, hsCRP, catches the low, simmering levels tied to excess body fat, insulin resistance, and heart risk. It's cheap, it's everywhere, and there's a good chance it's already sitting in your last physical's bloodwork.
Interleukin-6 (IL-6) is an inflammatory signal that your fat tissue helps pump out. It's one of the things that tells your liver to make CRP, which is why the two usually rise and fall together.
Neither of these is a disease. They're markers, and the researchers behind one of these analyses were blunt about that: hsCRP "is not a causal factor for CV disease and serves as a biomarker only."3 Watching the number fall is useful information, but it's not the same thing as watching a condition resolve.
What the Semaglutide Data Shows
The clearest picture comes from an analysis that pooled the STEP 1, 2, and 3 trials, published in 2023. Across the three studies, 3,782 people were randomized, and their CRP was measured at the start and again at week 68.1
Semaglutide 2.4 mg lowered CRP versus placebo by 44% in STEP 1, 39% in STEP 2, and 48% in STEP 3, all with strong statistical significance. People started with CRP between 3.4 and 4.5 mg/L, which is right in the range a doctor would flag.1
Here's a detail that's easy to skim past. STEP 2 also had a lower 1.0 mg dose arm, and the gap between the two doses wasn't statistically significant.1 If the anti-inflammatory effect were purely about how much drug you took, you'd expect a cleaner separation between the doses. That it wasn't there is a small hint that something other than raw drug exposure is driving the change.
Older research in people with type 2 diabetes points the same way. A patient-level analysis of the SUSTAIN and PIONEER trials, covering 2,482 people, found CRP dropped roughly 24% to 30%.3 Those were diabetes doses, not weight-loss doses, so it isn't a clean comparison, but the direction is consistent.
What the Tirzepatide Data Shows
A 2026 analysis of SURMOUNT-1 went deeper than CRP alone. Researchers tracked 16 different cardiovascular risk markers in 392 people who finished the trial, checking them at the start, 24 weeks, and 72 weeks.2
CRP dropped 50.6% on the 5 mg dose, 58.5% on 10 mg, and 64.5% on 15 mg by 72 weeks. Placebo fell 21.8% on its own, so once you subtract that out, the drug-driven drops were 36.9%, 46.9%, and 54.6%. IL-6 fell 25.4% to 30.2% after the same adjustment.2
Other markers moved too. Leptin, a hormone your fat cells release, dropped 44.4% to 61.4%. Insulin resistance, a measure of how well your body handles blood sugar, fell 26.4% to 39.1%. Adiponectin, a helpful fat hormone that tends to run low when you carry a lot of belly fat, climbed 21.1% to 47.7%.2 Taken together, that's a coherent picture of your metabolism behaving differently, not just one number wobbling.
A separate 2026 review pooled six studies and landed on a smaller average CRP drop of 32.9% versus placebo and an IL-6 drop of 17.8%.4 That's lower than the SURMOUNT-1 numbers, which is what usually happens when you blend trials with different people and different follow-up lengths.
Side by Side: the Numbers
| Marker | Semaglutide 2.4 mg (STEP 1-3, wk 68)1 | Tirzepatide (SURMOUNT-1, wk 72)2 |
|---|---|---|
| CRP / hsCRP vs placebo | −39% to −48% | −36.9% to −54.6% |
| IL-6 vs placebo | Not measured | −25.4% to −30.2% |
| Adiponectin | Not measured | +21.1% to +47.7% |
| Insulin resistance | Not reported in this analysis | −26.4% to −39.1% |
| Dose-response separation | Not statistically significant (2.4 mg vs 1.0 mg) | Present across 5, 10, 15 mg |
Note that these are separate trials with different designs and populations. Reading the table as a head-to-head ranking would be a mistake.
Is It the Medication or the Weight Loss?
Here's where most articles on this topic quietly overreach, so it's worth being precise.
The semaglutide investigators tested how CRP change tracked with weight change and found positive correlations, with the strongest correlations in each trial being with change in bodyweight.1 They also flagged earlier phase 2 work where the CRP reduction lost statistical significance once bodyweight was adjusted for. Their own summary sentence is the one to remember: whether semaglutide has an anti-inflammatory effect independent of weight loss "remains to be determined."1
The SUSTAIN and PIONEER analysis used a statistical method called mediation analysis, which tries to work out how much of one change is explained by another. It found that somewhere between 20.6% and 61.8% of the CRP drop was explained by changes in blood sugar (HbA1c) and bodyweight together, depending on the trial.3 The authors said there "may also be a direct semaglutide effect," which is a careful way of saying the leftover portion is unexplained, not proven to be something else. They also warned that this kind of analysis can't prove cause and effect.
So the fair reading is this. Research suggests GLP-1 and dual-agonist therapy may support meaningful reductions in inflammatory markers, and a portion of that reduction travels with weight loss and better blood sugar. Whether there's an additional direct effect on inflammation is still an open question. Anyone telling you it's settled is ahead of the evidence.
Why It May Still Matter Either Way
Even if the whole effect turned out to be just a result of the weight loss, that wouldn't make it any less real. Chronic low-grade inflammation is one of the ways extra belly fat is thought to raise your risk for heart and metabolic disease, so a lab number that reflects that process moving in the right direction is worth knowing about.
It also reframes what people are often measuring. Plenty of patients walk in tracking one number on a bathroom scale and nothing else. Weight is the input that's easiest to see, but the changes underneath it, in insulin sensitivity, in visceral fat, in markers like hsCRP, are a better description of what's actually shifting. That's a large part of why every protocol here starts with lab work and a body composition scan rather than a weigh-in.
Worth noting: the SURMOUNT-1 authors compared their CRP reductions against bariatric surgery figures of around 65.8%, and cautioned directly that the observational design of most surgical studies limits how comparable those numbers really are.2 A good example of researchers doing the hedging for us.
What This Does Not Mean
A few boundaries, stated plainly.
These medications are approved for chronic weight management and type 2 diabetes. They're not approved as treatments for inflammatory conditions, and nothing in this research supports using them that way. Rheumatoid arthritis, inflammatory bowel disease, and autoimmune conditions were not what these trials studied.
A falling hsCRP is a biomarker moving, not a disease being treated. The researchers behind the SUSTAIN and PIONEER analysis said as much themselves.3
Every trial cited here was funded by the manufacturer of the medication studied, with company employees among the authors. That's normal for phase 3 research, and the data is peer reviewed and open access, but it's context worth carrying.
How We Track It in Lisle
Every Defiant weight loss protocol starts with a provider consult and a lab review. We write the orders and the draw happens through your primary care physician or through Rythm Health, since we don't run blood draws in-clinic. If inflammatory markers are something you want visibility on, hsCRP is an easy add to that panel and a reasonable thing to recheck as your protocol progresses.
Alongside labs, every patient gets a Styku 3D body composition scan at baseline and monthly after that, which separates fat mass change from lean mass change in a way the scale cannot. Protocols are titrated every two weeks rather than monthly, which is the main structural difference between how we run this and how most telehealth programs do. Our medically supervised weight loss program starts at $295 per month and includes medication, provider oversight, bi-weekly titration check-ins, monthly scans, and nurse access.
We serve Lisle, Naperville, Downers Grove, Wheaton, Oak Brook, and the surrounding western suburbs.
- Semaglutide 2.4 mg reduced CRP versus placebo by 44%, 39%, and 48% at week 68 across the STEP 1, STEP 2, and STEP 3 trials.1
- Tirzepatide reduced high-sensitivity CRP by a placebo-adjusted 36.9% to 54.6% and IL-6 by 25.4% to 30.2% at 72 weeks in a SURMOUNT-1 post hoc analysis.2
- Whether the effect is independent of weight loss has not been established. The semaglutide investigators described the question as one that "remains to be determined."1
- A mediation analysis across SUSTAIN and PIONEER attributed 20.6% to 61.8% of the CRP effect to changes in blood sugar and bodyweight combined.3
- These medications are approved for chronic weight management and type 2 diabetes, not for treating inflammatory or autoimmune conditions.
- hsCRP is an inexpensive lab that may be worth tracking alongside body composition during a weight loss protocol.
Frequently Asked Questions
Track What Is Actually Changing.
Every Defiant protocol starts with lab work, a Styku body composition scan, and a provider consult, then titrates every two weeks. Programs start at $295 per month.
Keep Reading
Last updated August 27, 2026.
References
- Verma S, Bhatta M, Davies M, et al. Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials. eClinicalMedicine. 2023;55:101737. DOI
- Sattar N, Linetzky B, Ruotolo G, et al. Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis. Journal of the American College of Cardiology. 2026;88(6):652-666. DOI
- Mosenzon O, Capehorn MS, De Remigis A, et al. Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. Cardiovascular Diabetology. 2022;21:172. DOI
- Masson W, Lobo M, Nogueira JP, et al. Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis. Reviews in Endocrine and Metabolic Disorders. 2026;27(1):5-15. DOI